Skip to main content

Rachna Shroff, MD, MS

Professor, Medicine
Division Chief, Hematology Oncology
Professor, Cancer Biology
Professor, BIO5 Institute

PO Box 245024
Building: Sydney E. Salmon Building (#222A)
Room #: 1968B

(520) 626-6453
rshroff@arizona.edu

Selected Publications

Halder R, Shroff R.T., What is the role PARP inhibitors in pancreatic cancer? [ahead of print]
 
Abou-Alfa G, Macarulla T, Javle M, Kelley R, Lubner S, Adeva J, Cleary J, Catenacci D, Borad M, Bridgewater J, Harris W, Murphy A, Oh DY, Whisenant J, Lowery M, Goyal L, Shroff, R.T., El-Khoueiry A, Fan B, Wu B, Chamberlain C, Jiang L, Gliser C, Pandya S, Valle J, Zhu A. Invosidenib in IDH1-mutant, Chemotherapy-Refractory Cholangiocarcinoma (ClarlDHy): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. The Lancet Oncology, Vol 21(6):796-807, 2020 June 1. https://www.sciencedirect.com/science/article/pii/S1470204520301571?via…
 
Mizrahi J, Surana R, Valle, J, Shroff R.T. Pancreatic cancer. Lancet 2020; Vol 395: 2008-20.
 
Mizrahi, J. D., and R. T. Shroff, "New Treatment Options for Advanced Biliary Tract Cancer.", Curr Treat Options Oncol, vol. 21, issue 8, pp. 63, 2020 Jun 29. PMID: 32602010
 
Goldstein J, Zhao L, Wang X, Gheiman Y, Overman M, Javle M, Shroff R.T., Varadhachary G, Wolff R, McAllister F, Futreal A, Fogelman D. Germline DNA Sequencing Reveals Novel Mutations Predictive or Overal Survival in a Cohort of Patients with Pancreatic Cancer. Clinical Cancer Research 2020 March; 26(6),1385-1394
 
Shroff, R. T., M. M. Javle, L. Xiao, A. O. Kaseb, G. R. Varadhachary, R. A. Wolff, K. P. S. Raghav, M. Iwasaki, P. Masci, R. K. Ramanathan, et al., "Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.", JAMA Oncol, vol. 5, issue 6, pp. 824-830, 2019 Jun 01. PMCID: PMC6567834 PMID: 30998813
 
Scott, A. J., and R. T. Shroff, "Moving the Needle Forward With Locoregional Treatment in Unresectable Cholangiocarcinoma-The Jury Is Still Out.", JAMA Oncol, 2019 Oct 31. PMID: 31670748
 
Shroff, R. T., M. Yarchoan, A. O'Connor, D. Gallagher, M. L. Zahurak, G. Rosner, C. Ohaji, S. Sartorius-Mergenthaler, R. Parkinson, V. Subbiah, et al., "The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma.", Br J Cancer, vol. 118, issue 2, pp. e2, 2018 01. PMCID: PMC5785753 PMID: 29315294
 
Javle, M., M. Lowery, R. T. Shroff, K. Heinz Weiss, C. Springfeld, M. J. Borad, R. K. Ramanathan, L. Goyal, S. Sadeghi, T. Macarulla, et al., "Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.", J Clin Oncol, vol. 36, issue 3, pp. 276-282, 2018 01 20. PMCID: PMC6075847 PMID: 29182496
 

Sponsored Research Through MSRP

Rebecca Whitmer, (MSRP 2021): "Immune Response to the COVID-19 Vaccine."
 

Advanced Research Distinction Track (RDT)

Amisha Singh (RDT Class of 2020): "Retrospective Analysis of Outcomes with FOLFIRINOX vs. Nab-Paclitaxel plus Gemcitabine in Advanced Pancreatic Cancer"

Degrees

  • University of Texas, Houston, Texas (M.S. Patient-Based Biological Research)
  • Thomas Jefferson University, Philadelphia, Pennsylvania (M.D. Medicine)
  • Brown University, Providence, Rhode Island (B.S. Biochemistry)

Awards

  • The Indo-American Cancer Association Rising Star Award - The Indo-American Cancer Association (IACA), Winter 2017
  • ASCO Merit Award for GI ASCO - American Society of Clinical Oncology, Winter 2010
  • ASCO Young Investigator Award - American Society of Clinical Oncology (ASCO), Winter 2010
  • The A. Lavoy Moore Endowment Fund Fellowship Award - Cancer Medicine MDA, Summer 2010

Research Interests

Dr. Shroff is a clinical and translational investigator focused on developing novel therapies for pancreatic and biliary cancers. She holds multiple positions nationally due to her expertise in these areas, including serving as the Hepatobiliary subcommittee Co-Chair for the Southwest Oncology Group (SWOG) and as a Program Committee member for GI ASCO. She also is a member of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation. Dr. Shroff has led numerous clinical trials focusing on pancreaticobiliary tumors and is the national PI for SWOG 1815 which is investigating a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. This is based on a phase 2 study she led that is now published in JAMA Oncology. Dr. Shroff has been invited to speak at national and international meetings on topics related to targeted therapies for pancreatic and biliary cancers and has numerous peer-reviewed publications in this area.